Clinical trials
Observational Lupus Erythematosus, Systemic trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Unknown status | 7 |
| Active, not recruiting | 2 |
| Completed | 2 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nanfang Hospital, Southern Medical University | 2 |
| Yipeng Liu | 2 |
| AstraZeneca | 1 |
| Children's Hospital of Fudan University | 1 |
| Chinese SLE Treatment And Research Group | 1 |
| Monash University | 1 |
| Peking Union Medical College Hospital | 1 |
| Peking University People's Hospital | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Sun Yat-sen University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 21 |
| Autoimmune Diseases | 2 |
| Arthritis, Juvenile | 1 |
| Connective Tissue Diseases | 1 |
| Dermatomyositis | 1 |
| Infections | 1 |
| Nausea | 1 |
| Scleroderma, Diffuse | 1 |
| Scleroderma, Systemic | 1 |
| Sjogren's Syndrome | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.